Frontera Therapeutics, a clinical-stage biotech startup with operations in both China and the US, has pocketed $160 million in a Series B round of financing to bring the total fundraising size of the three-year-old firm to $195 million.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
